Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Suicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    362 result(s) found for: Suicide. Displaying page 3 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000577-38 Sponsor Protocol Number: PSZ-3002 Start Date*: 2007-08-16
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia
    Medical condition: Adolescents Schizphrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) EE (Completed) PL (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003382-17 Sponsor Protocol Number: 1439A-021 Start Date*: 2015-08-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naï...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) DK (Completed) NL (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000926-31 Sponsor Protocol Number: GWMS1137 Start Date*: 2011-06-29
    Sponsor Name:GW Pharma Ltd.
    Full Title: A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to...
    Medical condition: Spasticity in multiple sclerosis (MS).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001925-27 Sponsor Protocol Number: 06-MI-04 Start Date*: 2009-10-05
    Sponsor Name:Great Ormond Street Hospital For Children NHS Trust
    Full Title: Phase I/II clinical trial of T cell suicide gene therapy following haploidentical stem cell transplantation
    Medical condition: Graft-versus-host disease (GVHD) resulting from haploidentical bone marrow or blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000211-16 Sponsor Protocol Number: F1J-MC-HMFN Start Date*: 2017-03-02
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002560-34 Sponsor Protocol Number: F1J-US-HMFR(b) Start Date*: 2008-09-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis
    Medical condition: Central neuropathic pain due to Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021044-17 Sponsor Protocol Number: CLOCK_depression Start Date*: 2010-08-11
    Sponsor Name:Medizinische Universität Wien
    Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.
    Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000766-29 Sponsor Protocol Number: 104-201610 Start Date*: 2016-07-29
    Sponsor Name:Otonomy Inc.
    Full Title: A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE’S DISEASE
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004653-32 Sponsor Protocol Number: 69HCL16_0628 Start Date*: 2017-01-20
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Etude préliminaire de l’efficacité d’un α1 bloquant (la prazosine) en prévention de la survenue d’un état de stress post-traumatique chez des patients présentant un état de stress aigu.
    Medical condition: état de stress aigu à la suite d’un événement traumatisant par expérience directe
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10044541 Traumatic shock PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002939-18 Sponsor Protocol Number: GWEP1447 Start Date*: 2016-04-29
    Sponsor Name:GW Research Ltd.
    Full Title: A phase 2, double-blind, randomized, placebo-controlled pharmacokinetic trial in two parallel groups to investigate possible drug- drug interactions between stiripentol or valproate and GWP42003-P ...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002485-39 Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 Start Date*: 2019-06-14
    Sponsor Name:Ovid Therapeutics, Inc.
    Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP...
    Medical condition: developmental and epileptic encephalopathies
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-003221-29 Sponsor Protocol Number: XPF-008-201 Start Date*: 2020-03-12
    Sponsor Name:Xenon Pharmaceuticals Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Ex...
    Medical condition: Adult focal (partial onset) epilepsy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003019-47 Sponsor Protocol Number: SPD489-329 Start Date*: 2012-02-10
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With R...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) EE (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004325-80 Sponsor Protocol Number: ANAVEX2-73-AD-EP-004 Start Date*: 2022-01-10
    Sponsor Name:Anavex Germany GmbH
    Full Title: Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005929-89 Sponsor Protocol Number: CLOU064C12302 Start Date*: 2022-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SI (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) HR (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001519-38 Sponsor Protocol Number: CL2-47445-011 Start Date*: 2015-01-06
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized,...
    Medical condition: Mild to moderate Alzheimer's disease in patients with depressive symptoms
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012296 Dementia of the Alzheimer's type, with depressed mood PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BG (Completed) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000230-34 Sponsor Protocol Number: 15906A Start Date*: 2014-09-23
    Sponsor Name:H. Lundbeck A/S
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working...
    Medical condition: Major depressive disorder and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed) LT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004703-51 Sponsor Protocol Number: COMB157G2399 Start Date*: 2019-01-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003034-27 Sponsor Protocol Number: BN29552 Start Date*: 2016-07-13
    Sponsor Name:Roche Farma, S.A en nombre de F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER?S DISEASE
    Medical condition: Alzheimer?s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) HU (Completed) PT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) BE (Prematurely Ended) DK (Completed) AT (Prematurely Ended) SI (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) BG (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005899-36 Sponsor Protocol Number: CLOU064C12301 Start Date*: 2022-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 17:25:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA